Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01503229 · ClinicalTrials.gov registry record · Phase 2
Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
A Phase 2 study of Metastatic Prostate Carcinoma and Recurrent Prostate Carcinoma, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT01503229: Completed Phase 2 study of Metastatic Prostate Carcinoma and Recurrent Prostate Carcinoma, sponsored by University of Washington.
NCT01503229 is a Phase 2 study of Metastatic Prostate Carcinoma and Recurrent Prostate Carcinoma that has completed, run by University of Washington. The registered enrollment target is 32 participants, below the 132-participant average among 37 other Metastatic Prostate Carcinoma trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01503229, a Phase 2 study of Metastatic Prostate Carcinoma and Recurrent Prostate Carcinoma, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well abiraterone acetate works in treating patients with hormone-resistant prostate cancer that has spread from the primary site (place where it started) to other places in the body (metastatic). Abiraterone acetate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Primary Outcome
Tissue testosterone will be measured in biopsy tissues
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Prednisone
- DRUG Abiraterone Acetate
- OTHER Pharmacological Study
Study Locations (1)
Washington
- Fred Hutch/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2012-12 |
| Est. Completion | 2020-03-12 |
| Phase | Phase 2 |
What the finished NCT01503229 record still lists
NCT01503229 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 132-participant average among 37 other Metastatic Prostate Carcinoma trials with a reported enrollment target (76% lower).
The record links to 4 conditions, with Metastatic Prostate Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01503229 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT01503229 about?
NCT01503229 is a clinical study titled "Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer". This phase II trial studies how well abiraterone acetate works in treating patients with hormone-resistant prostate cancer that has spread from the primary site (place where it started) to other places in the body (metastatic). Abiraterone acetate may stop the growth of tumor cells by blocking some ...
What is the current status of trial NCT01503229?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2012-12. Estimated completion is 2020-03-12.
What conditions does trial NCT01503229 study?
This clinical trial studies the following conditions: Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Hormone-Resistant Prostate Cancer, Stage IV Prostate Adenocarcinoma.
What interventions are being tested in trial NCT01503229?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Prednisone (DRUG), Abiraterone Acetate (DRUG), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT01503229?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01503229 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Prostate Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01503229's enrollment target sits among peer trials
32 26th of 37 higher than 12 of 37 other Metastatic Prostate Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Prostate Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recurrent and Metastatic Prostate Cancer
RECRUITING · Phase 2
-
Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy
RECRUITING · Phase 2
-
FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial
RECRUITING · Phase 2
-
Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia